Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

Stock-plunging mRNA vaccine maker, already in bed with feds on vaccine royalties, says booster not "causally" related without ...

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Moderna slashed its 2025 revenue projection by $1bn on Monday, citing reduced demand for its Covid-19 and respiratory ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

There is no antiviral treatment for the miserable but thankfully short-lived illness, and no vaccine—yet. But scientists at Moderna are in the late stages of testing what could be the first such ...

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its vaccines against Covid-19 and respiratory syncytial virus continue to ...

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory syncyti ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.